GNOM


Genomics & Biotechnology ETF

Fund Summary

The Global X Genomics & Biotechnology ETF (GNOM) seeks to invest in companies that potentially stand to benefit from further advances in the field of genomic science, such as companies involved in gene editing, genomic sequencing, genetic medicine/therapy, computational genomics, and biotechnology.

Fund Objective

The Global X Genomics & Biotechnology ETF (GNOM) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Solactive Genomics Index.

Why GNOM?

High Growth Potential

GNOM enables investors to access high growth potential through companies that are positioned to benefit from further advances in the field of genomic science.

Targeted Exposure

GNOM provides access to emerging areas within the Health Care Sector at the intersection of science and technology.

ETF Efficiency

In a single trade, GNOM delivers access to dozens of companies with exposure to the genomics theme.

Fund Details As of 07/28/21

Key Facts

Ticker GNOM
Inception Date 04/05/19
CUSIP 37954Y434
ISIN US37954Y4347
Bloomberg Index Ticker SOLGNOM
Primary Exchange Nasdaq
Number of Holdings 39

Stats & Fees

Net Assets $236,507,990
Net Asset Value (NAV) $22.78
Shares Outstanding 10,380,000
Total Expense Ratio 0.50%

Distributions

30-Day SEC Yield -0.32%
Distribution Frequency Semi-Annually

Fund Prices As of 07/28/21

NAV $22.78 Daily Change $0.69 3.12%
Market Price $22.91 Daily Change $0.84 3.81%
30-Day Median Bid-Ask Spread 0.31%

Performance History

As of recent month & quarter-end (06/30/21)
As of recent month & quarter-end (06/30/21)
Fund NAV Market Price Index
1 Year 41.84% 42.01% 42.44%
Since Inception 24.39% 25.49% 25.02%
1 Year 41.84% 42.01% 42.44%
Since Inception 24.39% 25.49% 25.02%
Year-to-Date 5.38% 5.38% 5.57%
1 Month 15.52% 15.77% 15.53%
3 Months 10.93% 10.72% 11.02%
Since Inception 62.91% 66.16% 64.85%
Year-to-Date 5.38% 5.38% 5.57%
1 Month 15.52% 15.77% 15.53%
3 Months 10.93% 10.72% 11.02%
Since Inception 62.91% 66.16% 64.85%

Cumulative return is the aggregate amount that an investment has gained or lost over time. Annualized return is the average return gained or lost by an investment each year over a given time period.

The performance data quoted represents past performance. Past performance does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when sold or redeemed, may be worth more or less than their original cost and current performance may be lower or higher than the performance quoted. High short-term performance of the Fund, when observed, is unusual and investors should not expect such performance to be repeated.

Fund Characteristics As of 07/28/21

Return on Equity -41.70%
Weighted Avg. Market Cap 11,580 M
2020 2021
Price-to-earnings -30.43 -24.22
Price-to-book value 8.32 12.88

Source: AltaVista Research, LLC

Fund Risk Stats As of 07/28/21

Versus Beta
S&P 500 1.03
MSCI EAFE 0.93
MSCI Emg. Mkts 0.93
Standard Deviation 31.70%

Source: AltaVista Research, LLC

Sector Breakdown As of 06/30/21

% of Net Assets
Health Care 100.0

Source: AltaVista Research, LLC

Country Breakdown As of 06/30/21

% of Net Assets
United States 83.8
Netherlands 5.2
China 4.5
Switzerland 4.5
Japan 1.2
France 0.6
Singapore 0.3

Source: AltaVista Research, LLC

Top Holdings As of 07/28/21

Net Assets (%) Ticker Name SEDOL Market Price ($) Shares Held Market Value ($)
6.59 NTLA INTELLIA THERAPEUTICS INC BYZM6C2 136.17 114,468 15,587,107.56
5.24 ALNY ALNYLAM PHARMACE B00FWN1 182.10 68,021 12,386,624.10
4.78 1548 HK GENSCRIPT BIOTECH CORP BD9Q2J2 4.17 2,714,818 11,307,669.97
4.64 A AGILENT TECHNOLOGIES INC 2520153 151.46 72,419 10,968,581.74
4.43 CDNA CAREDX INC BP3YM74 86.23 121,356 10,464,527.88
4.37 QGEN QIAGEN N.V. BYXS688 51.62 200,268 10,337,834.16
4.07 SRPT SAREPTA THERAPEUTICS INC B8DPDT7 69.06 139,349 9,623,441.94
4.05 NTRA NATERA INC BYQRG48 110.97 86,280 9,574,491.60
4.04 BMRN BIOMARIN PHARMAC 2437071 78.73 121,321 9,551,602.33
3.87 PACB PACIFIC BIOSCIEN B4N8MH9 31.51 290,239 9,145,430.89
3.71 ARWR ARROWHEAD PHARMA BYQBFJ8 68.37 128,486 8,784,587.82
3.65 CRSP CRISPR THERAPEUTICS AG BDHF4K6 119.75 72,020 8,624,395.00
3.52 BPMC BLUEPRINT MEDICINES CORP BWY52P3 82.91 100,347 8,319,769.77
3.17 NVTA INVITAE CORP BVVCNT1 28.14 266,220 7,491,430.80
2.97 EDIT EDITAS MEDICINE INC BZ8FPH3 41.78 167,993 7,018,747.54
2.96 NSTG NANOSTRING TECHN BBL59X6 61.94 113,079 7,004,113.26
2.92 RARE ULTRAGENYX PHARM BJ62Z18 81.30 84,970 6,908,061.00
2.79 VCYT VERACYTE INC BFTWZY0 39.45 167,359 6,602,312.55
2.68 DRNA DICERNA PHARMACE BJ62Z07 37.30 169,985 6,340,440.50
2.50 ILMN ILLUMINA INC 2613990 492.22 12,027 5,919,929.94
2.47 MYGN MYRIAD GENETICS INC 2614153 31.45 185,689 5,839,919.05
2.42 RCKT ROCKET PHARMACEU BDFKQ07 38.90 146,875 5,713,437.50
2.40 SRNE SORRENTO THERAPEUTICS INC BCT5QQ7 8.58 660,223 5,664,713.34
2.24 GILD GILEAD SCIENCES INC 2369174 70.06 75,673 5,301,650.38
1.95 VRTX VERTEX PHARM 2931034 202.24 22,836 4,618,352.64
1.84 BLUE BLUEBIRD BIO INC BBFL7S1 26.00 167,022 4,342,572.00
1.70 ALLO ALLOGENE THERAPEUTICS INC BFZNYB7 22.57 178,545 4,029,760.65
1.32 RGNX REGENXBIO INC BZ0G875 34.00 91,810 3,121,540.00
1.26 SGMO SANGAMO THERAPEUTICS INC 2573083 9.95 298,784 2,972,900.80
1.24 4974 JP TAKARA BIO INC B03ML21 25.30 115,855 2,931,359.82
1.21 QURE UNIQURE NV BJFSR88 29.74 95,894 2,851,887.56
0.60 CLLS CELLECTIS - ADR BWFKZT2 13.70 102,675 1,406,647.50
0.48 DTIL PRECISION BIOSCIENCES INC BJ0M2S0 10.13 112,978 1,144,467.14
0.46 ZIOP ZIOPHARM ONCOLOGY INC B0HZZ46 2.27 482,467 1,095,200.09
0.29 FIXX HOMOLOGY MEDICINES INC BFMMJ23 6.60 102,479 676,361.40
0.29 WVE WAVE LIFE SCIENCES LTD BYZG9R0 5.82 115,652 673,094.64
0.28 PRQR PROQR THERAPEUTICS NV BQRX1W2 5.29 126,527 669,327.83
0.22 ADVM ADVERUM BIOTECHN BD6NXD7 2.37 222,889 528,246.93
0.22 CASH 1.00 508,958 508,947.60
0.19 VYGR VOYAGER THERAPEUTICS INC BY7RB53 3.23 141,332 456,502.36
Holdings are subject to change.


Investing involves risk, including the possible loss of principal. The investable universe of companies in which GNOM may invest may be limited. The Fund invests in securities of companies engaged in Genomics, Healthcare and Biotechnology sectors. These sectors can be affected by government regulations, rapid product obsolescence, intense industry competition and loss or impairment of patents or intellectual property rights. International investments may involve risk of capital loss from unfavorable fluctuation in currency values, from differences in generally accepted accounting principles or from social, economic or political instability in other nations. GNOM is non-diversified.

Shares of ETFs are bought and sold at market price (not NAV) and are not individually redeemed from the Fund. Brokerage commissions will reduce returns. Beginning October 15, 2020, market price returns are based on the official closing price of an ETF share or, if the official closing price isn’t available, the midpoint between the national best bid and national best offer (“NBBO”) as of the time the ETF calculates current NAV per share. Prior to October 15, 2020, market price returns were based on the midpoint between the Bid and Ask price. NAVs are calculated using prices as of 4:00 PM Eastern Time. The returns shown do not represent the returns you would receive if you traded shares at other times. Indices are unmanaged and do not include the effect of fees, expenses or sales charges. One cannot invest directly in an index.

Since the Fund’s shares did not trade in the secondary market until several days after the Fund’s inception, for the period from inception to the first day of secondary market trading in Shares, the NAV of the Fund is used to calculate market returns.

Carefully consider the Fund’s investment objectives, risks, and charges and expenses before investing. This and other information can be found in the Fund’s summary or full prospectuses. Please read the prospectus carefully before investing.

Global X Management Company LLC serves as an advisor to Global X Funds. The Funds are distributed by SEI Investments Distribution Co. (SIDCO), which is not affiliated with Global X Management Company LLC or Mirae Asset Global Investments. Global X Funds are not sponsored, endorsed, issued, sold or promoted by Solactive AG, nor does Solactive AG make any representations regarding the advisability of investing in the Global X Funds. Neither SIDCO, Global X nor Mirae Asset Global Investments are affiliated with Solactive AG.